Immunology

Edited by: Karen Young Kreeger MAKING A MIGHTY MOUSE: Yale's Richard Flavell and coworkers developed a CD40 ligand-less knockout mouse. J.C. Xu, T.M. Foy, J.D. Laman, E.A. Elliott, J.J. Dunn, T.J. Waldschmidt, J. ore, R.J. Noelle, R.A. Flavell, "Mice deficient for the CD40 ligand," Immunity, 1:423-31, 1994 (Cited in more than 80 publications as of August 1996) Comments by Richard A. Flavell, Howard Hughes Medical Institute, Yale University School of Medicine To more closely investigate the

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Edited by: Karen Young Kreeger


MAKING A MIGHTY MOUSE: Yale's Richard Flavell and coworkers developed a CD40 ligand-less knockout mouse.
J.C. Xu, T.M. Foy, J.D. Laman, E.A. Elliott, J.J. Dunn, T.J. Waldschmidt, J. ore, R.J. Noelle, R.A. Flavell, "Mice deficient for the CD40 ligand," Immunity, 1:423-31, 1994 (Cited in more than 80 publications as of August 1996)

Comments by Richard A. Flavell, Howard Hughes Medical Institute, Yale University School of Medicine

To more closely investigate the role of cell surface receptors in the human immune response, scientists at Yale University genetically engineered a knockout mouse without the gene for CD40L, a ligand molecule that binds to CD40. They designed these mice in collaboration with investigators at Dartmouth Medical School and the University of Iowa Medical School.

"The molecule CD40 is found on many antigen-presenting cells, although it was initially thought to be only on B cells," says Richard A. Flavell, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies